Amgen vs Gilead Sciences — CEO Pay Comparison
Robert Bradway (Amgen) earns $0 more in total compensation than Daniel O'Day (Gilead Sciences).
| Metric | AmgenAMGN | Gilead SciencesGILD |
|---|---|---|
| CEO | Robert Bradway | Daniel O'Day |
| Industry | Biotechnology | Biotechnology |
| Total Compensation | $12.0M | $12.0M |
| Base Salary | $1.2M | $1.2M |
| Stock Awards | $6.0M | $6.0M |
| Option Awards | $1.4M | $1.4M |
| Non-Equity Incentive | $1.8M | $1.8M |
| Pay-for-Performance Grade | B (70/100) | B (70/100) |
| CEO-Worker Pay Ratio | 96:1 | 96:1 |
| Median Worker Pay | $125K | $125K |
| Say-on-Pay Approval | 95.8% | 87.0% |
| 3yr Total Shareholder Return | +8.3% | +12.4% |
| Revenue | $28.2B | $27.1B |
| Market Cap | $160.0B | $120.0B |
| Employees | 27,000 | 17,000 |
Analysis
Robert Bradway (Amgen) earns $12.0M in total compensation, while Daniel O'Day (Gilead Sciences) earns $12.0M.
On pay-for-performance alignment, Amgen scores B (70/100) while Gilead Sciences scores B (70/100). Both companies have similar pay-for-performance alignment.
Amgen's CEO-to-worker pay ratio is 96:1 compared to Gilead Sciences's 96:1. Shareholders approved CEO pay at 95.8% (Amgen) and 87.0% (Gilead Sciences).